Compositions useful for mucosal healing
The present invention relates to a composition comprising at least one poloxamer compound for use in the treatment of a fistula in an individual.
1. A method for the treatment of a digestive fistula in an individual in need thereof, the method comprising administering to the individual:
at least one mesenchymal stem cell derived extracellular vesicle; and
a composition comprising:
at least one poloxamer compound of formula (I):
wherein 91<a<111 and 46<b<66,
wherein the at least one poloxamer compound is poloxamer 407 ,
wherein the at least one poloxamer compound is comprised in a concentration from about 20% to about 25%,
wherein the at least one mesenchymal stem cell derived extracellular vesicle comprises an amount of about 1.3x10 11 vesicles/ml,
optionally at least one contrast agent, and
optionally at least one pharmaceutically acceptable carrier or excipient.
2. The method according to claim 1 , for the treatment of an entero-cutaneous fistula.
3. The method according to claim 1 , wherein the composition is administered by endoscopy or into an external orifice.
4. A method for treatment of a digestive fistula or a mucosal injury or a stenosis in an individual in need thereof, the method comprising endoscopic administration or administration via an internal and/or external fistula orifice to the individual of:
an effective amount of at least one mesenchymal stem cell derived extracellular vesicle; and
a composition comprising:
at least one poloxamer hydrogel of formula (I):
wherein 91<a<111 and 46<b<66,
wherein the at least one poloxamer compound is poloxamer 407 ,
wherein the at least one poloxamer hydrogel is comprised in a concentration from about 20% to about 25%,
wherein the at least one mesenchymal stem cell derived extracellular vesicle comprises an amount of about 1.3x10 11 vesicles/ml,
optionally at least one contrast agent,
optionally at least one pharmaceutically acceptable carrier or excipient.
5. The method according to claim 1 , wherein the at least one polyxomer is a hydrogel.
6. The method according to claim 1 , wherein the at least one pharmaceutically acceptable carrier or excipient is PBS.
7. The method according to claim 1 , wherein the mesenchymal stem cell derived extracellular vesicle is comprised in a mesenchymal stem cell conditioned medium.